ASHBURN, Va., May 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announces that its open label study evaluating QRX003 as a treatment for Netherton Syndrome has reached 50% enrollment. The company’s open… Read More..

DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utility KELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce additional findings from last year's human clinical study HYPER-H21-4 ("the Study")… Read More..

- Proposed Deal Expected to Add $10+ Million in Annual Revenues, Anticipated to be Accretive to LiveOne’s EBITDA and Revenues - Acquisition Would Bring In-House IP Development and Ownership to LiveOne and Its Subsidiaries and Expected to Include More Than 25 Weekly Podcasts and 33 Million Monthly Downloads - Assets… Read More..